YOLO vs. PBE ETF Comparison
Comparison of AdvisorShares Pure Cannabis ETF (YOLO) to PowerShares Dynamic Biotech & Genome (PBE)
YOLO
AdvisorShares Pure Cannabis ETF
YOLO Description
Cannabis and its various applications have been used throughout human civilization for over 5,000 years. As society, business and regulatory landscapes evolve in the 21st century, the upside potential of cannabis as an emerging investment avenue has arrived. The portfolio manager believes today’s new era can be viewed in similar regard to post-Prohibition, commencing a growing acknowledgement and understanding of cannabis and its uses among a mainstream audience. The industries that comprise the multi-billion dollar cannabis universe represent a new frontier, where proper caution and due diligence must be exercised surrounding its regulations and risks, in seeking attractive long-term cannabis investment opportunities. The AdvisorShares Pure Cannabis ETF (Ticker: YOLO) became the first actively managed ETF with a dedicated cannabis investment mandate domiciled in the United States. The AdvisorShares Pure Cannabis ETF, or YOLO, seeks long-term capital appreciation by investing in both domestic and foreign cannabis equity securities. YOLO is designed to fully-invest for pure cannabis exposure under the guidance of a deeply experienced portfolio management team navigating the emerging cannabis marketplace.
Grade (RS Rating)
Last Trade
$2.59
Average Daily Volume
56,420
9
PBE
PowerShares Dynamic Biotech & Genome
PBE Description
The PowerShares Dynamic Biotechnology & Genome Portfolio (Fund) is based on the Dynamic Biotech & Genome IntellidexSM Index (Intellidex Index). The Fund will normally invest at least 90% of its total assets in common stocks that comprise the Index. The Intellidex Index is designed to provide capital appreciation by thoroughly evaluating companies based on a variety of investment merit criteria, including price momentum, earnings momentum, quality, management action, and value. The Underlying Intellidex Index is comprised of common stocks of 30 US biotechnology and genome companies. These are companies that are principally engaged in the research, development, manufacture and marketing and distribution of various biotechnological products, services and processes and companies that benefit significantly from scientific and technological advances biotechnology and genetic engineering and reseach. The Fund and the Index are rebalanced and reconstituted quarterly in February, May, August and November.Grade (RS Rating)
Last Trade
$68.56
Average Daily Volume
6,451
30
Performance
| Period | YOLO | PBE |
|---|---|---|
| 30 Days | -26.21% | 0.09% |
| 60 Days | -19.80% | -3.92% |
| 90 Days | -22.41% | -3.91% |
| 12 Months | -9.71% | 20.96% |
0 Overlapping Holdings
| Symbol | Grade | Weight in YOLO | Weight in PBE | Overlap |
|---|
YOLO Underweight 30 Positions Relative to PBE
| Symbol | Grade | Weight | |
|---|---|---|---|
| UTHR | C | -5.74% | |
| ILMN | C | -5.64% | |
| ALNY | D | -4.78% | |
| AMGN | F | -4.7% | |
| BIIB | F | -4.21% | |
| NBIX | C | -4.18% | |
| XNCR | B | -3.88% | |
| EXEL | B | -3.86% | |
| TGTX | B | -3.78% | |
| BMRN | F | -3.76% | |
| MNKD | C | -3.7% | |
| NTRA | A | -3.56% | |
| REGN | F | -3.38% | |
| INCY | C | -3.35% | |
| VCYT | B | -3.28% | |
| ACAD | C | -3.06% | |
| CPRX | C | -3.0% | |
| BPMC | B | -2.91% | |
| TECH | F | -2.89% | |
| VCEL | B | -2.79% | |
| OPK | C | -2.78% | |
| RGEN | D | -2.76% | |
| PTGX | D | -2.75% | |
| QGEN | D | -2.59% | |
| BCRX | D | -2.56% | |
| HALO | F | -2.42% | |
| COLL | F | -2.27% | |
| CDNA | D | -1.92% | |
| NVAX | F | -1.83% | |
| MYGN | F | -1.61% |
YOLO: Top Represented Industries & Keywords
PBE: Top Represented Industries & Keywords
Compare ETFs
